Advertisement
STVN vs WST
Which Stock Would AI Choose? Stevanato Group S.p.A. (STVN) vs. West Pharmaceutical Services, Inc. (WST) Stock Comparison
Key Takeaways
- Both STVN and WST operate in the biopharmaceutical packaging sector, providing containment and delivery systems for injectable drugs, making them direct peers in healthcare equipment.
- STVN has delivered year-to-date (YTD) returns of approximately 21%, outpacing WST's 1% YTD gain amid recent market volatility.
- WST maintains a significantly larger market capitalization of $20 billion compared to STVN's $4.3 billion, reflecting greater scale and stability.
- Recent quarterly earnings for both exceeded expectations, with STVN reporting 7% revenue growth and WST advancing facility expansions for high-value products.
- Comparative analyses indicate WST as a stronger long-term pick due to superior moat and momentum.
- Investor interest in GLP-1 (glucagon-like peptide-1) drug packaging drives sentiment for both stocks in recent weeks.
Introduction
Stevanato Group S.p.A. (STVN) and West Pharmaceutical Services, Inc. (WST) are key players in the specialized niche of biopharmaceutical containment and delivery systems, particularly for injectable therapies. This stock comparison is relevant for healthcare sector investors and traders seeking exposure to pharma packaging amid rising demand from biologics and GLP-1 drugs. By examining recent performance, financial metrics, and market positioning, readers can assess relative strengths in a competitive landscape driven by innovation and capacity expansions. Understanding these dynamics aids in evaluating portfolio diversification within medical devices.
STVN Overview and Recent Performance
Stevanato Group S.p.A. (STVN) designs and manufactures drug containment solutions like pre-fillable syringes, vials, and auto-injectors, alongside engineering services for biopharma clients worldwide. Headquartered in Italy, the company focuses on high-value solutions that comprised 46% of recent sales.
In recent market activity, STVN shares have exhibited volatility but posted YTD gains of 21% and one-year returns around 27%, trading near $16 with a price-to-earnings (P/E) ratio of 26. Sentiment shifted positively following Q4 2025 earnings in early March, where revenue rose 7% to €346.5 million, beating estimates, despite a pullback in certain segments. Core business improvements and GLP-1 exposure have bolstered confidence, though shares remain below 52-week highs amid broader sector pressures.
WST Overview and Recent Performance
West Pharmaceutical Services, Inc. (WST) provides proprietary products such as stoppers, seals, and self-injection systems, plus contract manufacturing for drug delivery devices. The U.S.-based firm serves major pharmaceutical and biotech companies across proprietary and contract segments.
Recent weeks have seen WST shares gain over 13% monthly, trading around $278 with a P/E of 41, supported by YTD returns of 1% and one-year gains of 38%. Key drivers include Dublin facility expansion for injectable capacity and Q4 2025 earnings beats, with analysts anticipating EPS growth ahead of upcoming reports. Strong demand for high-value products has sustained momentum, though shares trail 52-week peaks.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top 25 performers from over 351 AI trading bots that analyze thousands of tickers across diverse strategies like swing trading, trend following, and sector-specific plays. These bots employ machine learning for technical and fundamental signals, delivering impressive stats: annualized returns ranging from 15% to 168%, win rates of 54% to 88%, and profit factors up to 11.7. Timeframes vary from daily to multi-week holds, with drawdowns managed via take-profit/stop-loss corridors. Ideal for current volatile conditions, they target high-momentum areas like semiconductors, energy, and finance. Explore these curated bots to align with your trading style and enhance decision-making in stocks like STVN and WST.
Head-to-Head Comparison
Both firms share a business model centered on pharma packaging but differ in scale: WST’s $3 billion revenue dwarfs STVN’s $1.2 billion, enabling broader proprietary exposure versus STVN’s engineering focus. Growth drivers include GLP-1 demand, but WST benefits from high-value components and expansions, while STVN emphasizes vials and syringes.
Recent momentum favors WST with stronger monthly gains, though STVN leads YTD. Risk profiles highlight STVN’s higher beta as a smaller cap, versus WST’s stability. Sector exposure is identical in healthcare equipment, but WST shows superior moat scores and analyst conviction in relative performance and market positioning.
Tickeron AI Verdict
Tickeron’s AI analysis currently favors WST over STVN, citing greater trend consistency, larger scale, and positive catalysts like facility growth amid stable demand. While STVN offers growth potential, WST’s relative positioning suggests higher probability of outperformance in the near term based on observable metrics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STVN is a StrongBuy and WST is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
STVN’s FA Score shows that 0 FA rating(s) are green whileWST’s FA Score has 2 green FA rating(s).
- STVN’s FA Score: 0 green, 5 red.
- WST’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
STVN’s TA Score shows that 5 TA indicator(s) are bullish while WST’s TA Score has 3 bullish TA indicator(s).
- STVN’s TA Score: 5 bullish, 3 bearish.
- WST’s TA Score: 3 bullish, 5 bearish.
Price Growth
STVN (@Pharmaceuticals: Other) experienced а +1.86% price change this week, while WST (@Pharmaceuticals: Other) price change was -0.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.31%. For the same industry, the average monthly price growth was -0.98%, and the average quarterly price growth was -14.76%.
Reported Earning Dates
STVN is expected to report earnings on Aug 11, 2026.
WST is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-2.31% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| STVN | WST | STVN / WST | |
| Capitalization | 4.63B | 23.3B | 20% |
| EBITDA | 292M | 849M | 34% |
| Gain YTD | -15.805 | 20.034 | -79% |
| P/E Ratio | 28.96 | 44.08 | 66% |
| Revenue | 1.2B | 3.22B | 37% |
| Total Cash | 113M | 521M | 22% |
| Total Debt | 449M | 316M | 142% |
WST | ||
|---|---|---|
OUTLOOK RATING 1..100 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 47 | |
PRICE GROWTH RATING 1..100 | 13 | |
P/E GROWTH RATING 1..100 | 29 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| STVN | WST | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | 2 days ago 64% |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 78% | 2 days ago 64% |
| MACD ODDS (%) | N/A | 2 days ago 51% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 68% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 67% |
| Advances ODDS (%) | 6 days ago 79% | 2 days ago 68% |
| Declines ODDS (%) | 8 days ago 80% | 12 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 58% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 61% |
Advertisement
STVN and
Correlation & Price change
A.I.dvisor indicates that over the last year, STVN has been loosely correlated with WST. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if STVN jumps, then WST could also see price increases.
| Ticker / NAME | Correlation To STVN | 1D Price Change % | ||
|---|---|---|---|---|
| STVN | 100% | -3.42% | ||
| WST - STVN | 54% Loosely correlated | +0.54% | ||
| MTD - STVN | 37% Loosely correlated | +1.68% | ||
| NPCE - STVN | 35% Loosely correlated | -1.73% | ||
| BRKR - STVN | 35% Loosely correlated | -1.14% | ||
| NVST - STVN | 34% Loosely correlated | -1.54% | ||
More | ||||
WST and
Correlation & Price change
A.I.dvisor indicates that over the last year, WST has been loosely correlated with STVN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if WST jumps, then STVN could also see price increases.
| Ticker / NAME | Correlation To WST | 1D Price Change % | ||
|---|---|---|---|---|
| WST | 100% | +0.54% | ||
| STVN - WST | 54% Loosely correlated | -3.42% | ||
| RGEN - WST | 34% Loosely correlated | -4.05% | ||
| QDEL - WST | 33% Loosely correlated | -9.51% | ||
| XRAY - WST | 32% Poorly correlated | -1.74% | ||
| CAPN - WST | 32% Poorly correlated | N/A | ||
More | ||||